Alfuzosine Sandoz L.P.

Alfuzosine Sandoz L.P. may be available in the countries listed below.

Ingredient matches for Alfuzosine Sandoz L.P.

Alfuzosin

Alfuzosin hydrochloride (a derivative of Alfuzosin) is reported as an ingredient of Alfuzosine Sandoz L.P. in the following countries:

• Belgium


• France

International Drug Name Search

NuvaRing

NuvaRing is a brand name of ethinyl estradiol/etonogestrel, approved by the FDA in the following formulation(s):

NUVARING (ethinyl estradiol; etonogestrel - ring; vaginal)

• 
  Manufacturer: ORGANON USA INC
  
  Approval date: October 3, 2001
  
  Strength(s): 0.015MG;0.12MG ^[RLD]

Has a generic version of NuvaRing been approved?

No. There is currently no therapeutically equivalent version of NuvaRing available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of NuvaRing. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Drug delivery system for two or more active substances
  Patent 5,989,581
  Issued: November 23, 1999
  Inventor(s): Groenewegen; Rudolf Johannes Joseph
  Assignee(s): Akzo Nobel N.V.
  The present invention is dealing with a drug delivery system, preferably in a ring-shaped form suitable for vaginal administration, for the simultaneous release of a progestogenic steroid compound and an estrogenic steroid compound in a fixed physiological ratio over a prolonged period of time. The drug delivery system comprises at least one compartment comprising a thermoplastic polymer core containing the mixture of the progestogenic and estrogenic compounds and a thermoplastic polymer skin, the progestogenic compound being initially dissolved in the polymer core material in a relatively low degree of supersaturation.
  
  Patent expiration dates:
  
  
  • April 8, 2018
    
  
  

See also...

• NuvaRing Consumer Information (Drugs.com)
• NuvaRing Ring Consumer Information (Wolters Kluwer)
• NuvaRing Consumer Information (Cerner Multum)
• NuvaRing Advanced Consumer Information (Micromedex)
• Etonogestrel/Ethinyl Estradiol Ring Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and etonogestrel Consumer Information (Cerner Multum)
• Ethinyl estradiol and etonogestrel Vaginal Advanced Consumer Information (Micromedex)

daunorubicin liposomal

Generic Name: daunorubicin liposomal (DAW noe ROO bi sin LYE poe SOE mal)

Brand Names: Daunoxome

What is daunorubicin liposomal?

Daunorubicin liposomal is a cancer (antineoplastic) medication. Daunorubicin liposomal interferes with the growth of cancer cells and slows their growth and spread in the body.

Daunorubicin liposomal is used to treat advanced HIV-associated Kaposi's sarcoma.

Daunorubicin liposomal may also be used for purposes other than those listed in this medication guide.

What is the most important information I should know about daunorubicin liposomal?

Daunorubicin liposomal should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.

Serious side effects have been reported with the use of daunorubicin liposomal including: allergic reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); severe heart damage with prolonged use; decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; fever or chills; or signs of infection); severe nausea, vomiting, diarrhea, and loss of appetite; and others. Talk to your doctor about the possible side effects from treatment with daunorubicin liposomal.

Who should not use daunorubicin liposomal?

Do not use daunorubicin liposomal without first talking to your doctor if you have

• kidney disease;


• liver disease;


• 
  

  heart disease;

  
  


• 
  

  poor bone marrow function;

  
  


• 
  

  received radiation therapy that encompassed the heart; or

  
  


• 
  

  previously received treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (Daunoxome), idarubicin (Idamycin), or mitoxantrone (Novantrone).

  
  

The use of daunorubicin liposomal may be dangerous if you have any of the conditions listed above.

Daunorubicin liposomal is in the FDA pregnancy category D. This means that daunorubicin liposomal is known to be harmful to an unborn baby.Do not use daunorubicin liposomal without first talking to your doctor if you are pregnant. Discuss with your doctor the appropriate use of birth control during treatment with daunorubicin liposomal if necessary. Daunorubicin liposomal passes into breast milk and may harm a nursing baby. Breast-feeding should be avoided during treatment with daunorubicin liposomal.

How should I use daunorubicin liposomal?

Daunorubicin liposomal should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.

Your doctor will determine the correct amount and frequency of treatment with daunorubicin liposomal depending upon the type of cancer being treated and other factors. Talk to your doctor if you have any questions or concerns regarding the treatment schedule.

Your doctor will probably want you to have regularly scheduled blood tests and other medical evaluations during treatment with daunorubicin liposomal to monitor progress and side effects.

Skin accidentally exposed to daunorubicin liposomal should be rinsed thoroughly with soap and warm water.

Your healthcare provider will store daunorubicin liposomal as directed by the manufacturer. If you are storing daunorubicin liposomal at home, follow the directions provided by your healthcare provider.

What happens if I miss a dose?

Contact your doctor if you miss a dose of daunorubicin liposomal.

What happens if I overdose?

If for any reason an overdose of daunorubicin liposomal is suspected, seek emergency medical attention or contact your healthcare provider immediately.

Symptoms of a daunorubicin liposomal overdose tend to be similar to side effects caused by the medication, although often more severe.

What should I avoid while using daunorubicin liposomal?

Daunorubicin liposomal can lower the activity of your immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses and do not receive vaccines that contain live strains of a virus (e.g., live oral polio vaccine) during treatment with daunorubicin liposomal. In addition, avoid contact with individuals who have recently been vaccinated with a live vaccine. There is a chance that the virus can be passed on to you.

Skin accidentally exposed to daunorubicin liposomal should be rinsed thoroughly with soap and warm water.

Daunorubicin liposomal side effects

If you experience any of the following serious side effects from daunorubicin liposomal, contact your doctor immediately:

• 
  

  an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);

  
  


• 
  

  decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);

  
  


• 
  

  congestive heart failure (difficulty breathing, fluid retention, chest pain);

  
  


• 
  

  tissue or vein reactions near the site of administration;

  
  


• 
  

  liver damage (abdominal pain, yellowing of the skin or eyes);

  
  


• 
  

  nausea, vomiting, diarrhea, or loss of appetite;

  
  


• 
  

  inflamation or sores inside the mouth, throat, or intestines;

  
  


• 
  

  numbness or tingling;

  
  


• 
  

  fever, chills, or other signs of infection; or

  
  


• 
  

  back pain, flushing, and chest tightness while daunorubicin liposomal is being administered.

  
  

Other, less serious side effects may be more likely to occur. Continue taking daunorubicin liposomal and talk to your doctor if you experience:

• 
  

  temporary hair loss; or

  
  


• 
  

  red colored urine for 1 or 2 days following a dose.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Daunorubicin liposomal Dosing Information

Usual Adult Dose for Kaposi's Sarcoma:

For first line cytotoxic therapy for advanced HIV-associated Kaposi's sarcoma. (Note: Daunorubicin liposomal is not recommended for use in patients with less than advanced HIV-related Kaposi's sarcoma.

If the patient has an acceptable benefit-cardiac risk ratio and adequate blood cell counts, then the recommended dose is: 40 mg/m2 infused intravenously over 60 minutes every 2 weeks,

What other drugs will affect daunorubicin liposomal?

Do not use daunorubicin liposomal without first talking to your doctor if you have had previous treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (Daunoxome), idarubicin (Idamycin), or mitoxantrone (Novantrone). Because there is a maximum amount of these medications that should be administered to an individual, you may not be able to use daunorubicin liposomal. Do not receive "live" vaccines during treatment with daunorubicin liposomal. Administration of a live vaccine may be dangerous during treatment with daunorubicin liposomal.

Drugs other than those listed here may also interact with daunorubicin liposomal. Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines, including herbal products, during treatment with daunorubicin liposomal.

More daunorubicin liposomal resources

• Daunorubicin liposomal Side Effects (in more detail)
• Daunorubicin liposomal Use in Pregnancy & Breastfeeding
• Daunorubicin liposomal Drug Interactions
• Daunorubicin liposomal Support Group
• 0 Reviews for Daunorubicin liposomal - Add your own review/rating

• DaunoXome Prescribing Information (FDA)


• Daunorubicin Liposomal MedFacts Consumer Leaflet (Wolters Kluwer)


• Daunoxome Advanced Consumer (Micromedex) - Includes Dosage Information

Compare daunorubicin liposomal with other medications

• Kaposi's Sarcoma

Where can I get more information?

• Your healthcare provider may have additional information about daunorubicin liposomal that you may read.

See also: daunorubicin liposomal side effects (in more detail)

Ciprocur

Ciprocur may be available in the countries listed below.

Ingredient matches for Ciprocur

Cyproterone

Cyproterone is reported as an ingredient of Ciprocur in the following countries:

• Peru

International Drug Name Search

Natrijev diklofenak

Natrijev diklofenak may be available in the countries listed below.

Ingredient matches for Natrijev diklofenak

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Natrijev diklofenak in the following countries:

• Slovenia

International Drug Name Search